# EDGAR Filing Document

**Accession Number:** 0001479419
**File Stem:** 0001829126-26-000066
**Filing Date:** 2026-1
**Character Count:** 6253
**Document Hash:** 4b80ca7706b8d4a2433ce7b37143ebe8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-000066.hdr.sgml**: 20260106

**ACCESSION NUMBER**: 0001829126-26-000066

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260106

**DATE AS OF CHANGE**: 20260106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KALA BIO, Inc.
- **CENTRAL INDEX KEY:** 0001479419
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 270604595
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38150
- **FILM NUMBER:** 26511402

**BUSINESS ADDRESS:**
- **STREET 1:** 1167 MASSACHUSETTS AVENUE
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476
- **BUSINESS PHONE:** 781-996-5252

**MAIL ADDRESS:**
- **STREET 1:** 1167 MASSACHUSETTS AVENUE
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kala Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20091223

**UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the<br>Securities Exchange Act of 1934**

(Amendment No.)

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

**KALA BIO, INC.**

**(Name of Registrant as Specified in Its Charter)**

**(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)**

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required <br> ☐ Fee paid previously with preliminary materials <br> ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

**KALA**

BIO

**KALA BIO, INC., 1167 Massachusetts Avenue**

**Arlington, Massachusetts 02476**

**(781) 996-5252**

**SUPPLEMENT TO KALA BIO'S PROXY STATEMENT**

**FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JANUARY 30, 2026**

**Explanatory Note:**

On December 30, 2025, Kala Bio, Inc. (the "Company") filed its Definitive Proxy Statement for its 2025 Annual Meeting of Stockholders to be held on January 30, 2026 (the "Proxy Statement"). This supplement (the "Supplement") is being filed to update the Proxy Statement to: (i) describe two related party transactions entered into on December 30, 2025 with Baker Bros. Advisors LP ("Baker Bros.") and LifeSci Capital LLC ("LifeSci"), respectively, and (ii) update the number of shares of Common Stock outstanding as of December 30, 2025. Except as specifically supplemented or updated herein, this filing does not modify or update other disclosures in the Proxy Statement and does not reflect events occurring after the date of the Proxy Statement.

**Related Party Transactions**

On December 30, 2025, the Company entered into a settlement agreement with Baker Bros. pursuant to which the Company agreed to issue 900,000 shares of its Common Stock to resolve certain claims relating to participation rights under prior financing arrangements (the "Baker Settlement"). In connection with the Baker Settlement, the Company and Baker Bros. also entered into a voting agreement pursuant to which Baker Bros. granted an irrevocable proxy in favor of the Company to vote the settlement shares and other specified shares in line with the Company's Board of Directors' recommendations for a period of six months. As a result of the Baker Settlement, Baker Bros. beneficially owned 5,407,359 shares of Common Stock as of December 30, 2025.

On December 30, 2025, the Company also entered into a settlement agreement with LifeSci under which the Company agreed to issue 2,200,000 shares of Common Stock to settle certain payment obligations for financial advisory services.

**Outstanding Shares as of Record Date**

The Proxy Statement stated that there were 23,249,725 shares of the Company's Common Stock outstanding as of December 30, 2025. This is updated to state that, based on the issuances described above and additional private issuances on December 30, 2025, the Company had 27,849,725 shares of Common Stock outstanding as of December 30, 2025, the record date for the annual meeting.

***Important Information and Where You Can Find It***

This Supplement may be deemed to be solicitation material in respect of votes of stockholders to approve the matters to be voted on as described in the Proxy Statement. In connection with the matters to be voted on, the Company filed the Proxy Statement, which is available at the SEC's website (http://www.sec.gov) and has been sent to the stockholders of the Company. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE MATTERS DESCRIBED IN THE PROXY STATEMENT. Investors and security holders will be able to obtain a free copy of the Proxy Statement, as well as other relevant documents filed with the SEC containing information about the Company, without charge, at the SEC's website (http://www.sec.gov). Copies of documents filed with the SEC can also be obtained, without charge, by directing a request to the Company's Investor Relations department at (781) 996-5252.

***Participants in the Solicitation of Proxies in Connection with Financing***

The Company and certain of its respective directors, executive officers and employees may be deemed under the rules of the SEC to be participants in the solicitation of proxies with respect to the stockholder approvals. Information regarding the Company directors and officers is available in the Proxy Statement. Additional information is contained in the Proxy Statement and other relevant materials to be filed by the Company with the SEC. Free copies of these documents, when available, may be obtained as described in the preceding paragraph.